Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-27
2007-02-27
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C514S282000, C514S286000, C514S299000, C546S139000, C546S152000, C544S180000, C544S183000, C544S194000, C544S235000, C544S236000, C544S256000, C544S279000, C544S349000, C544S353000
Reexamination Certificate
active
10837467
ABSTRACT:
Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor.
REFERENCES:
patent: 5563151 (1996-10-01), Bowles et al.
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 0 434 385 (1991-06-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/32100 (1999-07-01), None
Baggiolini et al. Immunology Today 21(9) 418-420,2000.
Kedzierska et al. Antivir. Chem. Chemother. 12(3): 133-50.
Carroll R., et al. (1997).Science276:273-276.
Casella L., et al. (1996).Inorganic Chem35:7516-7525.
Donzella G., et al. (1998).Nature Medicine4:72-77.
Ghosh D., et al. (1998).Inorganic Chem37:6597-6605.
Gultneh Y., et al. (1995).Inorganic Chem34:3633-3645.
Gupta S., et al. (1998).J Biol Chem7:4282-4287.
Kanda W., et al. (1995).Angew Chem Int Ed Engl34:588-590.
Miedema F., et al. (1994).Immune Rev140:35-72.
Peled A., et al. (1998).Science283:845-848.
Ponath P. (1998).Exp Opin Invest Drugs7:1-18.
Schols D., et al. (1997).J Exp Med186:1383-1388.
Schols D., et al. (1997).Antiviral Research35:147-156.
Tachibana K., et al. (1998).Nature393:591-594.
Wyatt R., et al. (1998).Science280:1884-1888.
Biard-Piechaczyk et al., 1999 “Role of CXCR4 in HIV-1-induced Apoptosis of Cells with a CD4+, CXCR4+ Phenotype” Immunology Letters 70 (1999) 1-3.
Blanco, et al. , 2000 “The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelop-Induced Apoptosis” American Society for Microbiology, Jan. 2000, p. 51-56.
Fedyk, et al. “Maturation Decreases Responsiveness of Human Bone Marrow B Lineage Cells to Stromal-Derived Factor 1 (SDF-1)”, Journal of Leukocyic Biology, 66, p. 667.
Herbein et al., 1998 “Apoptosis of CD8+ T cells is Mediated by Macrophages Through Interaction of HIV gp 120 with Chemokine Receptor CXCR4” Nature 395, 1998, pp. 189-193.
Hesselgesser et al., 1997 “CD4-Independent Association Between HIV-1 gp 120 and CXCR4: Functional Chemokine Receptors are Expressed in Human Neurons”, Current Biology, 7(2), pp. 112-121.
Hesselgesser et al. 1998 “Neuronal Apoptosis Induced by HIV-1 gp 120 and the Chemokine SDF-1α is Mediated by the Chemokine Receptor CXCR4” Current Biology , 8 (10), pp. 595-598.
Lee et al., 1999 “Coreceptor/Chemokine Receptor Expression on Human Hematopoietic Cells: Biological Implications for Human Immunodeficiency Virus-Type 1 Infection” Blood, 93(4), pp. 1145-1156.
Nikolic et al., 1998 “The p35/Cdk5 Kinase Is a Neuron-Specific Rac Effector That Inhibits Pak1 Activity”, Nature 395, 194.
Ohagen et al., 1999 “Apoptosis Induced by Infection of Primary Brain Cultures with Diverse Human Immunodeficiency Virus Type 1 Isolates: Evidence for a Role of the Envelop” Journal of Virology, 73(2), pp. 897-906.
Schramm et al., 2000 “Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease”, Journal of Virology, Jan. 2000, p. 184-192.
Atsma Bem
Bogucki David
Bridger Gary J.
Crawford Jason
Harwig Curtis
AnorMED Inc.
Balasubramanian Venkataraman
Morrison & Foerster / LLP
LandOfFree
Chemokine receptor binding heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemokine receptor binding heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine receptor binding heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3866433